RxDoctor Payments Data

John Bonner, MD

Ophthalmology · Soddy Daisy, TNNPI 1831151216

Payments from drug & device makers

$3,518in general payments, 2019–2025

Across 80 payments — averaging $43.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • AbbVie$424
  • Rxsight Inc$369
  • Alcon$366
  • Ocular Therapeutix, Inc.$139
  • Carl Zeiss Meditec USA, Inc.$130
  • plus $546 from 10 others

What the payments were for

  • Grants$201%
  • Travel & lodging$1,16033%
  • Food & beverage$2,22463%
  • Education$1133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,518 in reported general payments places this provider in the 70th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$344,498
Medicare patients
710
Services billed
2,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast56$40,104
LumiganBimatoprost79$35,370
RestasisCyclosporine27$18,553
CombiganBrimonidine Tartrate/Timolol42$14,401
Prednisolone Acetate336$11,757
RocklatanNetarsudil Mesylat/Latanoprost25$9,498
Ketorolac Tromethamine254$9,031
RhopressaNetarsudil Mesylate13$5,892
SimbrinzaBrinzolamide/Brimonidine Tart17$5,194
VyzultaLatanoprostene Bunod14$5,005
MoxifloxacinMoxifloxacin Hcl171$4,764
BesivanceBesifloxacin Hcl20$4,223
ZioptanTafluprost/Pf16$4,041
Lotemax SmLoteprednol Etabonate12$2,925
Timolol Maleate96$2,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$424$68,324148 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$113$45,10970 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$76$15,39038 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Lotemax Sm$107$7,14832 claims
AlconSimbrinza$366$5,19417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Soddy Daisy

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →